[Federal Register Volume 77, Number 38 (Monday, February 27, 2012)]
[Notices]
[Pages 11555-11556]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-4425]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2009-D-0605]
Guidance for Institutional Review Boards, Clinical Investigators,
and Sponsors: Institutional Review Board Continuing Review After
Clinical Investigation Approval; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of a guidance entitled, ``Guidance for IRBs, Clinical
Investigators, and Sponsors: IRB Continuing Review after Clinical
Investigation Approval.'' The guidance announced in this document
finalizes the draft guidance of the same title dated January 2010. This
document also supersedes the Information Sheet, Continuing Review After
Study Approval. The guidance is intended to assist institutional review
boards (IRBs) in carrying out their continuing review responsibility by
providing recommendations regarding the criteria, process, and
frequency of continuing review to assure the protection of the rights
and welfare of subjects in clinical investigations.
DATES: Submit either electronic or written comments at any time. Submit
electronic comments to http://www.regulations.gov. Submit written
comments on the guidance to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852. See the SUPPLEMENTARY INFORMATION section for
electronic access to the guidance document.
ADDRESSES: Submit written requests for single copies of this guidance
to the Division of Drug Information, Center for Drug Evaluation and
Research (CDER), Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 51, Rm. 2201, Silver Spring, MD 20993-0002 (1-888-463-6332
or 301-796-3400); or the Office of Communication, Outreach and
Development (HFM-40), Center for Biologics Evaluation and Research
(CBER), Food and Drug Administration, 1401 Rockville Pike, Suite 200N,
Rockville, MD 20852-1448 (1-800-835-4709 or 301-827-1800); or the
Division of Small Manufacturers, International, and Consumer
Assistance, Center for Devices and Radiological Health (CDRH), Food and
Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 4613,
Silver Spring, MD 20993 (1-800-638-2041 or 301-796-7100). Send one
self-addressed adhesive label to assist the office in processing your
requests.
FOR FURTHER INFORMATION CONTACT: Sara Goldkind, Office of Good Clinical
Practice, Food and Drug Administration, 10903 New Hampshire Ave., Bldg.
32, Rm. 5129, Silver Spring, MD 20993-0002. 301-796-8342.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of a guidance entitled,
``Guidance for IRBs, Clinical Investigators, and Sponsors: IRB
Continuing Review after Clinical Investigation Approval.'' This
guidance is intended to assist IRBs in carrying out their continuing
review responsibility under 21 CFR 56.108(a) and 56.109(f) by providing
recommendations regarding the criteria, process, and frequency of
continuing review to assure the protection of the rights and welfare of
subjects in clinical investigations. The guidance should also help
clinical investigators and sponsors better understand their
responsibilities related to continuing review. This guidance supersedes
the Information Sheet, ``Continuing Review After Study Approval''
(September 1998, Office of Health Affairs, Food and Drug
Administration). To enhance human subject protection and reduce
regulatory burden, the Department of Health and Human Services, Office
for Human Research Protections (OHRP) and FDA have been actively
working to harmonize the Agencies' regulatory requirements and guidance
for human subject research. This guidance document was developed as a
part of these efforts.
In the Federal Register of January 13, 2010 (75 FR 1790), FDA
announced the availability of the draft guidance of the same title,
dated January 2010. FDA received numerous comments on the draft
guidance. All comments received during the comment period and questions
received by Agency staff related to implementation of the regulations
have been carefully reviewed and, where appropriate, incorporated into
the guidance. Changes from the draft guidance include more detailed
discussion about what should be submitted to assist the IRB in
conducting continuing review, clarification of recommendations
regarding submission of study-wide information for multi-site studies,
discussion of the circumstances in which expedited review procedures
may be used for continuing review, and revised guidance about how
continuing review dates should be determined. In addition, FDA's draft
guidance, ``IRB Continuing Review after Clinical Investigation
Approval'', did not address IRB approval of research with conditions.
Subsequent to OHRP's issuance of its guidance, ``IRB Approval of
Research with Conditions'' (November 2010), FDA received multiple
inquiries and comments recommending that FDA adopt the same policy. In
response to these comments, FDA is including a discussion of IRB
approval of research with conditions in the guidance.
This guidance is part of the Information Sheet Guidance Initiative,
announced in the Federal Register of February 3, 2006 (71 FR 5861),
which describes FDA's intention to update the process for developing,
issuing, and making available guidances intended for IRBs, clinical
investigators, and
[[Page 11556]]
sponsors. Known as ``Information Sheets,'' these guidances have
provided recommendations to IRBs, clinical investigators, and sponsors
to help them fulfill their responsibilities to protect human subjects
who participate in research regulated by the FDA. The Information Sheet
Guidance Initiative is intended to ensure that the Information Sheets
are updated, consistent with the FDA's good guidance practices (GGPs).
As part of the initiative, which will be ongoing, the Agency plans to
rescind Information Sheets that are obsolete, revise and reissue
guidances that address current issues, and develop new guidance
documents as needed.
The guidance is being issued consistent with FDA's good guidance
practices regulation (21 CFR 10.115). The guidance represents FDA's
current thinking on this topic. It does not create or confer any rights
for or on any person and does not operate to bind FDA or the public. An
alternative approach may be used if such approach satisfies the
requirements of the applicable statutes and regulations.
II. Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) either electronic or written comments regarding this
document. It is only necessary to send one set of comments. Identify
comments with the docket number found in brackets in the heading of
this document. Received comments may be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m., Monday through Friday.
III. Electronic Access
Persons with access to the Internet may obtain the document at
either http://www.regulations.gov or http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/GuidancesInformationSheetsandNotices/ucm113709.htm.
Dated: February 21, 2012.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2012-4425 Filed 2-24-12; 8:45 am]
BILLING CODE 4160-01-P